MORRISTOWN, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a specialty pharmaceutical company, today announced that it is offering up to $850 million aggregate principal amount of five and ten year senior unsecured notes in a registered public offering.
Watson has filed a registration statement (including a prospectus supplement and accompanying prospectus) with the SEC relating to the offering. This offering of senior unsecured notes, may be made only by means of a prospectus supplement and an accompanying prospectus. Before investing, investors should read the prospectus, the prospectus supplement and other documents that the company has filed with the SEC for more complete information about Watson Pharmaceuticals, Inc. and this offering. Investors may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the prospectus and prospectus supplement relating to the notes can be obtained by contacting BofA Merrill Lynch or Barclays Capital at:
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
For press release and other company information, visit Watson Pharmaceuticals’ Web site at http://www.watson.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
SOURCE Watson Pharmaceuticals, Inc.
CONTACT: Patty Eisenhaur of Watson Pharmaceuticals, Inc., +1-973-355-8141
Web site: http://www.watson.com/
